Lymphocyte activation gene 3 (Lag3) expression is increased in prion infections but does not modify disease progression by Liu, Yingjun et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2018
Lymphocyte activation gene 3 (Lag3) expression is increased in prion
infections but does not modify disease progression
Liu, Yingjun; Sorce, Silvia; Nuvolone, Mario; Domange, Julie; Aguzzi, Adriano
Abstract: Prion diseases, Alzheimer’s disease and Parkinson’s disease (PD) are fatal degenerative disor-
ders that share common neuropathological and biochemical features, including the aggregation of patho-
logical protein conformers. Lymphocyte activation gene 3 (Lag3, also known as CD223) is a member of
the immunoglobulin superfamily of receptors expressed on peripheral immune cells, microglia and neu-
rons, which serves as a receptor for ￿-synuclein aggregates in PD. Here we examined the possible role of
Lag3 in the pathogenesis of prion diseases. Through quantitative real-time PCR and RNA-sequencing,
we found that the expression levels of Lag3 were relatively low in the adult mouse brains, yet its ex-
pression was increased after prion infection. However, we failed finding significant differences regarding
the incubation time, PrPSc load, neurodegeneration, astrocyte and microglia reactions and inflammatory
gene expression between the Lag3 knockout mice and wild-type littermate controls after prion infection.
We conclude that loss of Lag3 has no significant influence on prion disease pathogenesis. Considering
that Lag3 is an immune checkpoint receptor, our results suggest that immune checkpoint inhibition (an
increasingly prevalent therapeutic modality against many types of cancer) might not exert positive or
negative effects on the progression of prion diseases.
DOI: https://doi.org/10.1038/s41598-018-32712-8
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-157233
Journal Article
Published Version
 
 
The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0)
License.
Originally published at:
Liu, Yingjun; Sorce, Silvia; Nuvolone, Mario; Domange, Julie; Aguzzi, Adriano (2018). Lymphocyte
activation gene 3 (Lag3) expression is increased in prion infections but does not modify disease progression.
Scientific Reports, 8:14600.
DOI: https://doi.org/10.1038/s41598-018-32712-8
1Scientific REPORtS |  (2018) 8:14600  | DOI:10.1038/s41598-018-32712-8
www.nature.com/scientificreports
Lymphocyte activation gene 3 
(Lag3) expression is increased 
in prion infections but does not 
modify disease progression
Yingjun Liu  1, Silvia Sorce1, Mario Nuvolone1,2, Julie Domange1 & Adriano Aguzzi1
Prion diseases, Alzheimer’s disease and Parkinson’s disease (PD) are fatal degenerative disorders that 
share common neuropathological and biochemical features, including the aggregation of pathological 
protein conformers. Lymphocyte activation gene 3 (Lag3, also known as CD223) is a member of the 
immunoglobulin superfamily of receptors expressed on peripheral immune cells, microglia and neurons, 
which serves as a receptor for α-synuclein aggregates in PD. Here we examined the possible role of Lag3 
in the pathogenesis of prion diseases. Through quantitative real-time PCR and RNA-sequencing, we 
found that the expression levels of Lag3 were relatively low in the adult mouse brains, yet its expression 
was increased after prion infection. However, we failed finding significant differences regarding the 
incubation time, PrPSc load, neurodegeneration, astrocyte and microglia reactions and inflammatory 
gene expression between the Lag3 knockout mice and wild-type littermate controls after prion 
infection. We conclude that loss of Lag3 has no significant influence on prion disease pathogenesis. 
Considering that Lag3 is an immune checkpoint receptor, our results suggest that immune checkpoint 
inhibition (an increasingly prevalent therapeutic modality against many types of cancer) might not 
exert positive or negative effects on the progression of prion diseases.
Prion diseases, also known as transmissible spongiform encephalopathies, are progressive neurodegenerative 
disorders affecting many mammalian species. Prion diseases share common neuropathological features like pro-
tein aggregation, neuronal and synaptic degeneration and glial cell activation with other neurological conditions 
such as Alzheimer’s disease (AD) and Parkinson’s disease (PD)1. The replication, transmission and aggregation of 
pathological prion protein, PrPSc, play central roles in prion disease pathogenesis2,3. Despite extensive research, 
the molecular mechanisms underlying the events driving disease progression are only partially known. What is 
more, validated targets regulating cell-to-cell spreading of prions, prion-induced neurotoxicity and the pathogen-
esis of prion diseases are still waiting to be identified. Consequently, interventional therapies for prion diseases 
are still lacking2.
Lymphocyte activation gene 3 (Lag3, also known as CD223) is a member of the immunoglobulin super-
family of receptors identified on activated human natural killer cells and T cells with diverse biologic effects4,5. 
Additionally, Lag3 is expressed by other immune cells including B cells and dendritic cells6,7. Lag3 is a 498-amino 
acid type-I transmembrane protein with four extracellular immunoglobulin superfamily-like domains. As an 
immune checkpoint receptor, Lag3 negatively regulates T cell proliferation, activation and homeostasis similarly 
to CTLA-4 and PD-18,9 and represents a promising cancer immunotherapeutic target5. Lag3 is associated with the 
T-cell receptor:CD3 complex10 and binds to major histocompatibility complex class-II molecules expressed on 
antigen-presenting cells11,12. Lag3 also binds to other molecules that may be expressed on tumor cells, including 
Galectin-3 and liver sinusoidal endothelial cell lectin (LSECtin)12,13.
The cellular expression pattern and function of Lag3 in the central nervous system (CNS) are still elusive. 
Some studies reported that Lag3 was highly expressed in microglia isolated from human and mouse brains14–16. 
The function of microglia-expressed Lag3 is not clear. However, in view of its regulatory role in the activation of 
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peripheral immune cells, Lag3 may also be involved in microglial reaction in neurodegenerative diseases, thus 
contributing to the disease progression. On the other hand, another study suggested that Lag3 was exclusively 
expressed by neurons in the CNS, serving as a cellular receptor for pathologic α-synuclein17. Neuronal expressed 
Lag3 binds to α-synuclein fibrils, triggers their endocytosis into neuronal cell body, facilitates the spreading of 
α-synuclein pathology and plays a vital role in α-synuclein transmission and PD pathogenesis.
Whether and how Lag3 may contribute to the pathogenesis of other similar neurodegenerative conditions, 
such as prion diseases, is unclear. In principle, mechanisms involving both microglia and neurons might play a 
role. Here we examined the expression levels of Lag3 in the mouse brain after prion infection and investigated 
its possible role in the progression of prion diseases by using Lag3 knockout (Lag3 KO) mice. We found that the 
expression levels of Lag3 were relatively low in the adult mouse CNS; however, its expression levels were increased 
after prion infection. Loss of Lag3 had no significant influence on prion disease pathogenesis. Lag3 knockout 
mice and the wildtype (WT) littermate controls showed similar incubation time after RML6 prion inoculation. 
Accordingly, we did not find any difference regarding the PrPSc load, neurodegeneration, astrocyte and microglia 
reactions and inflammatory gene expression in the brains of Lag3 WT and KO mice after prion infection. These 
results suggest that Lag3 plays a negligible role in prion disease pathogenesis and immune checkpoint blockade 
might not be an effective way to halt the progression of prion diseases.
Results
Increased Lag3 expression in RML6 prion infected mouse brain. To investigate the possible involve-
ment of Lag3 in the pathogenesis of prion diseases, we firstly examined its expression levels in the mouse brains 
inoculated with scrapie prions (Rocky Mountain Laboratory, Passage 6; RML6) or with non-infectious brain 
homogenate (NBH). Through quantitative real-time PCR (qRT-PCR), we found that the mRNA levels of Lag3 
were increased in mouse brains inoculated with RML6 prion at the terminal stage of the disease. The RNA expres-
sion levels of Lag3 were ~8-fold higher in prion-infected brains than that in NBH-inoculated brains (Fig. 1A).
To further characterize the changes of Lag3 during the course of disease progression, we measured the mRNA 
levels of Lag3 in two different brain regions (hippocampus and cerebellum) at different time points after prion 
inoculation by RNA sequencing (RNA-Seq). We found that the expression levels of Lag3 in both brain regions 
were relatively low in the mice inoculated with NBH, with 10–20 counts in the cerebellum and 70–110 counts 
in the hippocampus (Fig. 1B,C). However, in accordance with our qRT-PCR results, the mRNA levels of Lag3 
were significantly higher (~10 fold) in both brain regions at the terminal stage of prion infection, compared with 
the NBH controls (Fig. 1B,C). Expression of Lag3 had already increased at 16 weeks after prion inoculation and 
increased continuously during the disease progression (Fig. 1B,C). These results indicate that Lag3 expression is 
drastically induced during prion infection and may be involved in the pathogenesis of prion diseases.
Similar prion disease pathogenesis in Lag3 WT and KO mice. Based on the gene expression analyses 
mentioned above, we hypothesized that loss of Lag3 might influence the course of prion diseases. To test this, 
we inoculated the Lag3 WT and KO mice with either RML6 prion or NBH through the intracerebral route. The 
deletion of Lag3 gene in the Lag3 KO mice was confirmed by qRT-PCR (Supplementary Fig. 1). In addition, by 
western blotting we found that loss of Lag3 did not alter the PrPC protein expression levels in the mouse CNS 
(Supplementary Fig. 2). Nonetheless, we found that the Lag3 WT and KO mice showed similar incubation time 
after prion infection, with median survival time 173.5 days for Lag3 WT and 171 days for Lag3 KO mice (Fig. 2A). 
These results suggest that Lag3 provides no significant contribution to the pathogenesis of prion diseases even if 
its expression levels are dramatically enhanced during prion infection.
Similar levels of PrPSc and neurodegeneration in Lag3 WT and KO mice. Next, we set out to exam-
ine whether there was any neuropathological difference between the Lag3 WT and KO mice at the terminal stage 
of prion infection. Through western blot combining with proteinase K (PK) digestion, we found that there were 
similar levels of PK-resistant PrPSc in the brains of Lag3 WT and KO mice (Fig. 2B), which indicates that loss of 
Lag3 does not affect the generation of pathologic PrP aggregates in prion diseases. To examine whether loss of 
Figure 1. Increased Lag3 expression in prion-infected mouse brain. (A) qRT-PCR results of Lag3 expression 
in the mouse brains inoculated with either NBH or RML6 prion. **P < 0.01 (n = 6). (B,C) RNA-Seq data of 
Lag3 expression in hippocampus (B) and cerebellum (C) at different time points after prion infection. *P < 0.05; 
***P < 0.001 (n = 3 at each time points). NBH, Normal Brain Homogenate; RML6, Rocky Mountain Laboratory, 
Passage 6.
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Lag3 affects prion-induced neurotoxicity, we quantified the NeuN positive area in the CA1 region of hippocam-
pus, one of the most affected brain regions after prion infection, in Lag3 WT and KO mice inoculated with either 
RML6 prion or NBH. Indeed, we found that, after prion infection, the number of neurons in hippocampal CA1 
significantly decreased in both Lag3 WT and KO mice (Fig. 2C,D). However, the extents of neurodegeneration 
in Lag3 WT and KO mice were similar (Fig. 2C,D), suggesting that loss of Lag3 has no significant influence on 
prion-induced neurotoxicity. Taken together, these results indicate that Lag3 plays an insignificant role in the 
development of major neuropathological phenotypes induced by prion infection.
Similar astrocyte and microglia reactions in Lag3 WT and KO mice. In addition to its expression 
in neurons17, several studies reported that Lag3 was highly expressed in microglia both in the human and mouse 
brains14–16. To investigate whether loss of Lag3 may affect the glial responses after prion infection, we evaluated 
the astrocyte and microglia reactions by western blotting and immunohistochemistry in the brains of Lag3 WT 
and KO mice at the terminal stage of prion infection. We found that the protein levels of GFAP and Iba1 were sig-
nificantly upregulated in the brains inoculated with RML6 prion, compared with the ones inoculated with NBH, 
in both of the Lag3 WT and KO mice (Fig. 3A–C). However, the upregulation levels of both of these proteins were 
similar between the Lag3 WT and KO mice (Fig. 3A–C).
As expected, we found that the densities of GFAP+ reactive astrocytes and CD68+ reactive microglia signif-
icantly increased after prion infection. However, there was no difference detected between the Lag3 WT and KO 
mice (Fig. 3D–G). These results indicate that loss of Lag3 does not affect astrocyte and microglia responses in 
prion diseases.
Similar expression levels of inflammatory genes in prion-infected Lag3 WT and KO mice. To 
compare the inflammatory gene expression levels in the brains of the Lag3 WT and KO mice at the terminal stage 
of prion infection, we examined the mRNA levels of major inflammatory genes like tumor necrosis factor alpha 
(TNFα), interleukin 1 beta (IL1β), interleukin 12 beta (IL12β), cyclooxygenase 2 (Cox2), inducible nitric oxide 
synthase (iNOS) and transforming growth factor beta 1 (Tgfb1) by qRT-PCR. We found that, the expression levels 
of TNFα, IL12β and Tgfb1 were significantly increased, while the expression levels of IL1β, Cox2 and iNOS were 
drastically decreased after prion infection (Fig. 4). However, the mRNA levels of all these factors were similar 
between the Lag3 WT and KO mice with or without prion infection, except that the mRNA level of Cox2 was 
slightly higher in the brains of Lag3 KO mice, compared with the Lag3 WT mice, after prion infection (Fig. 4). 
Figure 2. Incubation times, PrPSc levels and neurodegeneration in Lag3 WT and KO mice after prion infection. 
(A) Survival curves of Lag3 WT and KO mice after prion infection. Median incubation time: 173.5 days for 
Lag3 WT mice and 171 days for Lag3 KO mice. Twenty mice containing both genders were pooled together for 
both of the Lag3 WT and KO mice. Log-rank (Mantel-Cox) test was used for the comparison of survival curves. 
(B) Representative image of a western blot examining PK-resistant PrPSc levels in the brains of Lag3 WT and 
KO mice. Full-length blots are presented in Supplementary Fig. 4. (C) Representative images of NeuN staining 
in the hippocampus of the Lag3 WT and Lag3 KO mice. Scale bars: 100 μm for the upper images and 50 μm 
for the lower images. (D) Quantitative data of the NeuN positive areas shown in (C). *P < 0.05 (n = 6). n.s, not 
significant. NBH, Normal Brain Homogenate; RML6, Rocky Mountain Laboratory, Passage 6.
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Together, these results suggest that the presence or absence of Lag3 does not exert a discernible effect onto the 
regulation of inflammatory genes induced or repressed by prion infection.
Discussion
This study was primarily inspired by a study performed by the Dawson lab, showing that Lag3 acts as a receptor 
for α-synuclein aggregates17. Although α-synuclein and PrPSc are molecularly and biogenetically distinct, they 
both form highly ordered aggregates which coalesce into amyloid fibrils. Since it appears likely that Lag3 interacts 
with the amyloid-specific pattern of aggregated α-synuclein, we reasoned that it might interact also with further 
amyloids, potentially including prions. A decisive advantage of the prion infection models is their precision: 
mice exposed to a defined prion inoculum succumb to scrapie after a highly predictable incubation time; even 
minor shifts in the incubation period allow detecting genetic modifiers of pathogenesis. However, we found that 
prion-infected Lag3-deficient mice progressed to terminal disease with the same kinetics and attack rates as WT 
mice, and exhibited the same type of CNS pathology. Therefore, we can confidently conclude that Lag3 is not a 
mediator of prion ingress into cells relevant to disease.
Using various technologies such as qRT-PCR and next generation RNA-Seq, we found that Lag3 expression 
levels were conspicuously increased in the brains of prion-infected mice. Even then, however, the increase of 
Figure 3. Astrocyte and microglia activation in the brains of terminal-sick Lag3 WT and KO mice.  
(A) Representative images of GFAP and Iba1 western blot in the brains of Lag3 WT and KO mice inoculated 
with NBH or RML6. Full-length blots are presented in Supplementary Fig. 5. (B,C) Quantitative data 
of GFAP (B) and Iba1 (C) protein levels shown in  (A). ***P < 0.001 (n = 6). n.s, not significant. (D,E) 
Representative images of immunofluorescent staining of GFAP (D) and CD68 (E) in the brains of Lag3 WT 
and KO mice inoculated with NBH or RML6. Scale bar: 50 μm. (F,G) Quantitative data of GFAP (F) and 
CD68 (G) positive areas shown in (D,E) respectively. ***P < 0.001 (n = 6). n.s, not significant. NBH, Normal 
Brain Homogenate; RML6, Rocky Mountain Laboratory, Passage 6.
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Lag3 expression seemingly contributed nothing to the pathogenesis of prion diseases. We failed finding any 
significant difference between the Lag3 WT and KO mice regarding the PrPSc load, prion-induced neurotox-
icity, astrocyte and microglia reactions and inflammatory gene expression in the brain at the terminal stage of 
prion diseases.
Since Lag3 was reported to be expressed by peripheral immune cells4,6,7, neurons17 and microglia14–16, the 
cellular contribution(s) to the increased Lag3 levels in the prion-affected brains still needs to be determined. 
A factor preventing us answering this important question is the dearth of anti-Lag3 antibodies for immuno-
histochemical examinations of Lag3 expression in mouse brain sections. Based on the available data in the 
literature, infiltrating T cells may be a source of the CNS Lag3 expression during prion infection. Infiltrating 
T cells were reported to be present in prion-infected mouse brains and in brains of patients suffering from 
Creutzfeldt-Jakob disease (CJD)18. Additionally, sequencing studies suggested that Lag3 was highly expressed 
in microglia isolated from human and mouse brains14–16. In fact, since the expression of Lag3 was so specific to 
isolated microglia, some study even suggested using Lag3 as one of the markers for identifying microglia in the 
adult CNS16. Considering the dramatic microglial activation in the prion infected brain19, the increased Lag3 
levels may partially result from the increased microglia number induced by prion infection. Indeed, by using 
RNA-Seq, we found that mRNA levels of Lag3 were significantly increased as early as 16 weeks after prion inoc-
ulation (Fig. 1B,C), which is consistent with the time-course of microglia activation in prion infected mouse 
brain20. It is also possible that the expression level of Lag3 is higher in activated microglia comparing with 
resting microglia. However, Lag3 seemed to play no role in regulating microglial activation and inflammatory 
gene expression in prion diseases (Figs 3 and 4).
In recent years, accumulating evidence have indicated that peripheral immune system is implicated in the 
pathogenesis of neurodegenerative diseases such as AD and PD21–23. It was even suggested that boosting the 
systemic immunity through immune checkpoint inhibition might be a promising therapeutic intervention to 
combat these devastating disorders24. Indeed, previous studies indicated that blocking the checkpoint signaling 
on peripheral immune cells with anti-PD1 antibodies enhanced immune cell infiltration into the AD-affected 
mouse brain from choroid plexus through an interferon-γ dependent mechanism, resulting in amyloid clearance 
and cognitive improvement25,26. However, similar results were not observed in another study conducted by the 
joint force of three different institutions with several amyloid transgenic mouse models27. Just like PD1, Lag3 was 
reported to be one of the key immune checkpoint molecules expressed on major peripheral immune cells, nega-
tively regulating T cell proliferation, activation and homeostasis8,9. Therefore, our results not only imply that Lag3 
may not be a functionally relevant prion receptor, but they also suggest that immune checkpoint blockade might 
not be an effective way to halt the progression of prion diseases, which is consistent with previous findings that T 
cell deficiency has no impact on prion disease pathogenesis28.
On a slightly more positive note, we have found that Lag3 deficiency does not worsen prion pathology. This 
may be comforting to those patients who harbor pathogenic mutations in the prion gene and are at risk of devel-
oping genetic prion diseases (such as CJD, Fatal Familial Insomnia, and Gerstmann-Sträussler-Scheinker dis-
ease). These patients develop cancer with the same incidence as everybody else, and the need will inevitably arise 
to treat them with checkpoint inhibitors whose use is becoming extremely prevalent in both solid and hematolog-
ical malignancies5,29,30. The present study suggests that the use of such agents in patients with PRNP mutations is 
unlikely to have any prion-specific deleterious effect.
Figure 4. Expression levels of inflammatory genes in the brains of terminal-sick Lag3 WT and KO mice. qRT-
PCR results of TNFα (A), IL12β (B), Tgfb1 (C), IL1β (D), Cox2 (E) and iNOS (F) expression in the brains of 
Lag3 WT and KO mice inoculated with NBH or RML6. *P < 0.05; **P < 0.01; ***P < 0.001 (n = 3 for NBH 
groups and n = 6 for RML6 groups). n.s, not significant. NBH, Normal Brain Homogenate; RML6, Rocky 
Mountain Laboratory, Passage 6.
www.nature.com/scientificreports/
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Methods
Ethics statement. All animal experiments were performed according to Swiss federal guidelines (‘Ethical 
Principles and Guidelines for Experiments on Animals’ 3rd edition, 2005) and were approved by the Animal 
Experimentation Committee of the Canton of Zurich (permit 41/2012, ZH040-15, ZH139-16). All efforts were 
made to minimize animal discomfort and suffering.
Prion inoculation. Lag3 KO (a gift from Prof. Ted Dawson, Johns Hopkins University, School of Medicine, 
Baltimore, USA) and WT littermate control mice were intracerebrally inoculated with 30 µl of 0.1% normal brain 
homogenate (NBH) or brain homogenate from RML6 prion infected mice (RML6). Diagnosis of scrapie was 
undertaken according to appropriate clinical criteria, namely ataxia, limb weakness, front leg paresis and rolling. 
Mice were sacrificed at the terminal stage of prion disease. For RNA-sequencing experiments, C57BL/6J mice 
purchased from Charles River (Germany) were used and sacrificed at different time points after prion infection.
Western blot. Western blot was performed as previously described31, with small modifications. The pri-
mary antibodies used were mouse monoclonal antibody against actin (1:10000, Merck Millipore, MAB1501R), 
PrPC (1:5000, POM1, homemade), GFAP (Sigma, AMAB91033); rabbit polyclonal antibody against Iba1 (1:1000, 
Wako, 019-19741). Appropriate secondary antibodies (1:10000, Jackson ImmunoResearch Laboratories) were 
incubated according to the primary antibodies. Membranes were visualized and digitized with ImageQuant 
(LAS-4000; Fujifilm). Optical densities of bands were analyzed by using ImageJ. For the western blot examining 
PrPSc, protein samples were digested with proteinase K (60 μg/ml) for 30 minutes at 37 °C.
Immunofluorescence. Immunofluorescent staining was performed according to the procedure published 
previously31. For mouse brain tissue staining, 25 μm-thickness sections were cut by using Cryostat (Leica). The 
following antibodies were used: anti-GFAP (1:300, Agilent Technologies, Z0334), anti-NeuN (1:500, Abcam, 
ab177487) and anti-CD68 (1:200, BioRad, MCA1957). Brain sections were incubated in the primary antibody 
overnight at 4 °C followed by incubation in the secondary antibody for 2 hours at room temperature. The images 
were captured by using the FLUOVIEW FV10i confocal microscope (Olympus Life Science) and quantified with 
ImageJ.
Quantitative real-time PCR (qRT-PCR). Total RNA from mouse brain was extracted by using TRIzol 
(Invitrogen) according to the manufacturer’s instruction and cDNA were synthesized by using the QuantiTect 
Reverse Transcription kit (QIAGEN). qRT-PCR was performed using the SYBR Green PCR Master Mix (Roche) 
on a ViiA7 Real-Time PCR system (Applied Biosystems). The following primers were used: Mouse actin: sense 
5′-AGATCAAGATCATTGCTCCTCCT-3′; antisense, 5′-ACGCAGCTCAGTAACAGTCC-3′. Mouse Lag3: sense, 
5′-CCAGGCCTCGATGATTGCTA-3′; antisense, 5′-CAGCAGCGTACACTGTCAGA-3′. Mouse TNFα: sense, 
5′-ACGTCGTAGCAAACCACCAA-3′; antisense, 5′-ATAGCAAATCGGCTGACGGT-3′. Mouse IL1β: sense, 
5′-TGCAGCTGGAGAGTGTGGATCCC-3′; antisense, 5′-TGTGCTCTGCTTGTGAGGTGCTG-3′. Mouse IL12β: 
sense, 5′-TGGTTTGCCATCGTTTTGCTG-3′; antisense, 5′-ACAGGTGAGGTTCACTGTTTCT-3′. Mouse Cox2: 
sense, 5′-GGGCCATGGAGTGGACTTAAA-3′; antisense, 5′-ACTCTGTTGTGCTCCCGAAG-3′. Mouse iNos: 
sense, 5′-TCCTGGACATTACGACCCCT-3′; antisense, 5′-CTCTGAGGGCTGACACAAGG-3′. Mouse Tgfb1: 
sense, 5′-GTGGACCGCAACAACGCCATCT-3′; antisense, 5′-CAGCAATGGGGGTTCGGGCA-3′.
RNA sequencing. RNA sequencing on hippocampal and cerebellar tissues of mice intracerebrally injected 
with RML6 or NBH was performed as previously described32,33. Briefly, total RNA was extracted using the RNeasy 
Plus universal mini kit (QIAGEN) and subjected to quality control using Bioanalyzer 2100 (Agilent Technologies) 
and Qubit (1.0) Fluorometer (Life Technologies). Libraries were prepared after poly A–enrichment with the 
TruSeq RNA Sample Prep kit v2 (Illumina) and sequencing was performed using the TruSeq SBS kit v4-HS 
(Illumina) on Illumina HiSeq 2500 at 1 × 100 bp. Data analysis was performed as previously described34,35 using 
the R packages GenomicRanges36 and edgeR from Bioconductor Version 3.0.
Statistical analyses. Unless otherwise mentioned, unpaired, two-tailed student’s t-tests were used for com-
paring data from two groups. All data was presented as mean ± SEM. Statistical analysis and data visualization 
was done by using GraphPad Prism 7 (GraphPad). P-values < 0.05 were considered statistically significant.
Availability of Data and Materials
All data generated or analyzed during this study are included in this published article (and its Supplementary 
Information files).
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